NEOGENOMICS INC (NEO)
CIK 1077183 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 130.2M shares as of Apr 24, 2026 (10-Q).
Cash runway
Self-funding
generates cash
Full breakdown: cash runway tool · source filing →
Warrants
Warrants outstanding: 450,000 underlying shares, as reported Dec 31, 2016 (10-K).
Reported exercise price: $1.5 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 130.7M = 130.2M O/S + 450,000 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| 0.25 Convertible Senior Notes | $345.0M | $69.0M | $14.59 | 0.25% | ~23.6M sh |
| Convertible Notes Due 2032 | $316.3M | $316.3M | $14.16 | 0.75% | ~22.3M sh |
| 1.25 Convertible Senior Notes | $201.3M | $201.3M | not tagged | 1.25% | — |
If every note above converted at its tagged price: ~46.0M new shares on 130.2M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Jul 28, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 130.2M | Apr 24, 2026 |
| + Warrants (aggregate, as tagged) (if exercised) | 450,000 | Dec 31, 2016 |
| + 0.25 Convertible Senior Notes (if fully converted) | 23.6M | Jan 11, 2021 |
| + Convertible Notes Due 2032 (if fully converted) | 22.3M | Jun 22, 2026 |
| Fully diluted estimate | 176.6M | +35.7% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 1 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full NEO workspace